Video

hfCas12Max: A Novel Nuclease For CRISPR-Based Cell And Gene Therapies

hfCas12Max, an engineered variant of Cas12i, offers a significant leap forward in genome editing technology. With its high-fidelity profile and broad PAM sequence recognition, hfCas12Max enables precise genetic modifications in previously inaccessible genomic regions.

In this video, Casey Jowdy from Synthego discusses the technical advancements behind hfCas12Max and its potential to revolutionize biomedical research and therapeutic development.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Synthego Corporation